tbuckley/cabot-search huggingface dataset:
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence,<i>In Vivo</i>Expansion, and Enhanced Function
Authors: Daniel A. Vallera, Martin Felices, Ron McElmurry, Valarie McCullar, Xianzheng Zhou, Joerg Uwe Schmohl, Bin Zhang, Alexander J. Lenvik, Angela Panoskaltsis-Mortari, Michael R. Verneris, Jakub Tolar, Sarah Cooley, Daniel J. Weisdorf, Bruce R. Blazar, Jeffrey S. Miller
Journal: Clinical Cancer Research (2016)

Abstract Purpose: The effectiveness of NK cell infusions to induce leukemic remission is limited by lack of both antigen specificity and in vivo expansion. To address the first issue, we previously generated a bispecific killer engager (BiKE) containing single-chain scFv against CD16 and CD33 to create an immunologic synapse between NK cells and CD33+ myeloid targets. We have now incorporated a novel modified human IL15 crosslinker, producing a 161533 trispecific killer engager (TriKE) to induce expansion, priming, and survival, which we hypothesize will enhance clinical efficacy. Experimental Design: Reagents were tested in proliferation and functional assays and in an in vivo xenograft model of AML. Results: When compared with the 1633 BiKE, the 161533 TriKE induced superior NK cell cytotoxicity, degranulation, and cytokine production against CD33+ HL-60 targets and increased NK survival and proliferation. Specificity was shown by the ability of a 1615EpCAM TriKE to kill CD33-EpCAM+ targets. Using NK cells from patients after allogeneic stem cell transplantation when NK cell function is defective, the 161533 TriKE restored potent NK function against primary AML targets and induced specific NK cell proliferation. These results were confirmed in an immunodeficient mouse HL-60-Luc tumor model where the 161533 TriKE exhibited superior antitumor activity and induced in vivo persistence and survival of human NK cells for at least 3 weeks. Conclusions: Off-the-shelf 161533 TriKE imparts antigen specificity and promotes in vivo persistence, activation, and survival of NK cells. These qualities are ideal for NK cell therapy of myeloid malignancies or targeting antigens of solid tumors. Clin Cancer Res; 22(14); 3440–50. ©2016 AACR. See related commentary by Talmadge, p. 3419
Prognostic Value of p53 for Local Failure in Mastectomy-Treated Breast Cancer Patients
Authors: R.C. Zellars, S.G. Hilsenbeck, G.M. Clark, D.C. Allred, T.S. Herman, G.C. Chamness, R.M. Elledge
Journal: Journal of Clinical Oncology (2000)

PURPOSE: The loss of p53 function is a recognized adverse prognostic factor in invasive breast cancer. Several studies have shown a relationship between the nuclear accumulation of p53 protein (a surrogate marker of p53 inactivation) and poor disease-free and overall survival. In general, however, these studies did not report the prognostic value of p53 for local failure, which we have therefore assessed retrospectively here. MATERIALS AND METHODS: Accumulation of p53 protein was evaluated by immunohistochemistry in 1,530 mastectomy-treated breast cancer patients (259 radiation therapy [RT]– and 1,271 mastectomy only [No RT]–treated patients). Statistical comparisons were made between p53 protein accumulation, estrogen/progesterone receptors, nodal status, tumor size, and local failure rate (LFR). Local failure was defined as tumor recurrence involving the chest wall and/or the ipsilateral supraclavicular/axillary lymph nodes. The median follow-up period was 62 months. RESULTS: In the No RT group, the LFR was 9.1% and 16.5% in p53-negative and p53-positive patients, respectively (P &lt; .001). Multivariate analysis revealed that p53 protein accumulation was significantly associated with an increased risk of local relapse (relative risk [RR], 1.7; 95% confidence interval [CI], 1.2 to 2.4). Nodal status and tumor size were also significant factors. In the RT group, the LFR was 9.3% and 21.5% in p53-negative and p53-positive patients, respectively (P = .009). Multivariate analysis revealed that p53 protein accumulation was significantly associated with an increased risk of local relapse (RR, 2.5; 95% CI, 1.1 to 5.7), as was nodal status. CONCLUSION: Nuclear accumulation of p53 protein is independently associated with a significantly increased local failure rate in breast cancer patients treated with mastectomy, with or without radiation.
Barriers exist to patient participation in clinical trials
Authors: M. J. Guarino, G. A. Masters, C. J. Schneider, D. D. Biggs, S. S. Grubbs, A. L. Himelstein, S. E. Martin, L. M. Michaels, A. J. Guarino, L. Rejtos
Journal: Journal of Clinical Oncology (2005)

6015 Background: Multiple factors determine whether or not cancer pts enter a clinical trial. To find some of these causes, a seven physician MedOnc/Hem practice with access to CALGB, NSABP, ECOG, RTOG, GOG, industry and investigator initiated trials developed an internal survey. Methods: A one page data sheet was completed by physicians for a planned 1000 consecutive pts referred with a cancer diagnosis. Collected data includes diagnosis, stage, demographics, availability of clinical trials, enrollment status or reasons for non-enrollment. Results: From 4/04 thru 8/04 surveys were collected on 518 pts. 28 pts were determined not to have cancer. 490 pts with 493 cancers were reported. Diagnosis and % of total sample includes [hospital tumor registry data base in brackets]: Lung 24.9%[15.4%],Breast 24.7%[20.1%],Head & Neck 7.5%[4.5%],Prostate 5.5%[13.1%],Colorectal 4.7%[9.5%],Lymphoma 4.7%[3.0%]; M 44.7%[46.8%],F 55.3%[53.2%]; median age 64 yrs; White 84.3%, Minority 15.7%; stage 0, I, II 46.1%, stage III, IV 53.9%. 22.2%(109/490) of cancer pts were considered eligible for clinical trial following initial presentation: 8.2%(40/490) enrolled. Of eligible pts, 36.7%(40/109) entered trial: M 60.5% vs F 34.0%(p=.018); <70 yrs 40.5% vs ≥ 70 yrs 24.0%(p=.16); White 37.0% vs Minority 35.3%; stage 0, I, II 6.6% vs stage III & IV 9.4%(p=.33). 44%(48/109) of eligible pts declined trial. 19.3%(21/109) of eligible pts were not entered on trial due to physician preference. For eligible pts ≥ 70 the physician exclusion rate was 36.0%(9/25); for those <70 it was 14.3%(12/84)(p=.022). Other reasons for not entering a trial include: no active trial 47.3%(232/490) and pt failing eligibility criteria 30.4%(149/490: poor functional status 14.9%, abnormal labs 3.5%, prior malignancy 1.4%, other 10.6%). Conclusion: An overall trial participation rate of 8.2% at intial presentation, while exceeding national averages, remains suboptimal. Lack of available trials, stringent entry criteria and pt choice are barriers to trial enrollment in this physician practice. Minority status is not a barrier but female gender may be. Advanced age appears to be a limiting factor for both pts and physicians. Further research to investigate clinical trial participation is warranted. No significant financial relationships to disclose.
Juvenile male sexual assaulters
Authors: D O Lewis, S S Shankok, J H Pincus
Journal: American Journal of Psychiatry (1979)

This study compares the psychiatric, neurological, and psychoeducational status of sexually assaultive male juveniles and other violent juveniles. The authors found that juvenile sexual assaulters suffered from neuropsychiatric problems similar to those of other violent juveniles, had committed violent acts other than sexual assault, and had had seriously aberrant behavior since early childhood. The findings contradict prevailing assumptions that sexual assaults by juveniles are rare occurrences and that juvenile sex offenders have low rates of recidivism. Theoretical and treatment implications are discussed.
Abscessus pulmonum: Unexpected outcome of surgical treatment; a case presentation
Authors: Vladimir Mirošljevic, Aleksandra Vukicevic, Ljiljana Todorovic, Olivera Ljuboja
Journal: European Respiratory Journal (2011)

This paper presents a case of 12-year-old girl, who was admitted to the pulmonology department of the Clinic for children's ilness KC Banja Luka in february 2010th year, because of the x-ray verified large tumor change in the left hemithorax. Insight into previous medical documentation, patient previously had two surgeries for a congenital deformity of the thoracolumbal spine. After admission in our department, in a differential diagnosis, we have done chest CT, GI passage, the serology of Echinococcus granulosus, ultrasonography and laboratory analasys, after which the patient was reffered to the surgical treatment at the Institute for Mother and child in New Belgrade.

![Figure][1] 



During the surgery a apscess cavity filled with green colored compress was found, which had been present for 2.5 years since spine surgery.

 [1]: pending:yes
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
Authors: Michael Untch, Christian Jackisch, Andreas Schneeweiss, Bettina Conrad, Bahriye Aktas, Carsten Denkert, Holger Eidtmann, Hermann Wiebringhaus, Sherko Kümmel, Jörn Hilfrich, Mathias Warm, Stefan Paepke, Marianne Just, Claus Hanusch, John Hackmann, Jens-Uwe Blohmer, Michael Clemens, Silvia Darb-Esfahani, Wolfgang Daniel Schmitt, Serban Dan Costa, Bernd Gerber, Knut Engels, Valentina Nekljudova, Sibylle Loibl, Gunter von Minckwitz
Journal: The Lancet Oncology (2016)
Patterns of practice in radiation therapy for non-small cell lung cancer among members of American Society of Therapeutic Radiology and Oncology
Authors: F. Kong, B. West, J. Bonner, H. Choy, L. E. Gaspar, R. Komaki, A. Sun, D. Morris, L. Wang, H. M. Sandler, B. Movsas
Journal: Journal of Clinical Oncology (2007)

7693 Purpose: To investigate the dominant pattern of current practice in radiation therapy (RT) for lung cancer among members of American Society of Therapeutic Radiology and Oncology (ASTRO). Methods: A 35-item survey was designed by a panel of 8 board certified radiation oncologists regarding RT for lung cancer. Surveys were sent through email to 3,800 radiation oncologist members on September 10, 2006, with the results collected online on December 10, 2006. Here we report results on radiation decisions for non-small cell lung cancer (NSCLC). Results: The response rate was 19% (n = 727). The respondents saw an average of 8 consults (ranged 1–25) monthly during the survey time (summing up to a total of &gt;60,000 new cases yearly). For stage I peripherally located NSCLC, 33%, 10% and 20% of respondents reported conventional fractionated, hypofractioned and stereotactic RT, respectively. Another 25% of respondents would have offered stereotactic RT if this technique were available at their center. For stage I centrally located tumors, 78% of respondents did not agree with, but 10% selected, stereotactic RT. For stage II and III, 76% of respondents selected 60–70 Gy in 1.8–2 Gy with chemotherapy. With regard to the combined modality approach for stage II and III disease, 76–77% of respondents selected concurrent chemoRT followed by adjuvant chemotherapy, and 11–16% sequential followed by concurrent chemoRT for patients with good performance status. For stage IV NSCLC with remarkable local disease, the consideration of RT ranged from 0 Gy, 3 Gyx10, 3 Gyx15, 2.5 Gyx20, to 2 Gyx30 in 27%, 17%, 8%, 13%, and 21% of respondents, respectively. Conclusions: The dominant pattern of practice for stage II/III disease is concurrent chemoRT, consistent with results of phase III trials. The treatment decisions for stage I and IV disease are diverse, partially due to technology advancement and the lack of large phase III trials. No significant financial relationships to disclose.
Esophageal Cancer Among Black Men in Washington, D.C. II. Role of nutrition
Authors: R G Ziegler, L E Morris, W J Blot, L M Pottern, R Hoover, J F Fraumeni
Journal: JNCI Journal of the National Cancer Institute (1981)

A case-control study of esophageal cancer was conducted among the black male residents of Washington, D.C., to find reasons for the exceptionally high risk in this population. The next of kin of 120 esophageal cancer cases who died during 1975–77 and of 250 D.C. black males who died of other causes were interviewed. Five indicators of general nutritional status—fresh or frozen meat and fish consumption, dairy product and egg consumption, fruit and vegetable consumption, relative weight (wt/ht2), and number of meals eaten per day—were each significantly and inversely correlated with the relative risk of esophageal cancer. Associations with other food groups were not apparent. The least nourished third of the study population, defined by any of these five measures, was at twice the risk of the most nourished third. None of these associations was markedly reduced by controlling for ethanol consumption, the other major risk factor in this population; smoking; socioeconomic status; or the other nutrition measures. When the three food group consumption measures were combined into a single overall index of general nutritional status, the relative risk of esophageal cancer between extremes was 14. Estimates of the intake of vitamin A, carotene, vitamin C, thiamin, and riboflavin were inversely associated with relative risk; but each micronutrient index was less strongly associated with risk than were the broad food groups that provide most of the micronutrient. Thus no specific micronutrient deficency was identified. Instead, generally poor nutrition was the major dietary predictor of risk and may partially explain the susceptibility of urban black men to esophageal cancer.
Tolerability and pharmacokinetics of intraperitoneal carboplatin and paclitaxel with intravenous bevacizumab.
Authors: C. N. Krasner, M. Seiden, M. Roche, M. A. Morgan, U. Matulonis, J. Wolf, C. Drescher, R. D. Alvarez, D. K. Armstrong, J. G. Supko
Journal: Journal of Clinical Oncology (2010)

5037 Background: GOG172 demonstrated improved survival for patients (pts) with ovarian cancer treated with intraperitoneal (IP) chemotherapy, as compared with standard IV dosing. Two ongoing phase III trials have added bevacizumab (bev) to upfront treatment and the next planned GOG study has been designed to include bev in conjunction with multiple IP regimens. A pilot trial done in collaboration between Ovarian SPORE sites was undertaken to evaluate the safety, tolerability and pharmacokinetics of such a regimen. Methods: Carboplatin AUC 6 on day 1 and paclitaxel 60 mg/m2 on days 1, 8, 15 was given, IV in cycle 1 and IP in the 5 subsequent 21-day cycles. The initial IV cycle was designed to allow for intra-patient IV vs. IP pk comparison. Pts received bev 15 mg/kg IV on day 8 in cycle 2 and day 1 in cycles 3-6. Results: Trial is complete with40 evaluable pts. Pts were able to complete most of the planned treatment, with 34 pts completing all 6 cycles. There was no progressive disease on trial. Toxicity was mild with no febrile neutropenia, no grade 3-4 neuropathy, hypertension, proteinuria or renal complications. There was no delayed wound healing or bowel perforation, and a single port-related problem. Significant grade 3-4 toxicity includes: abdominal pain (5), fatigue (6), neutropenia (10), thrombocytopenia (5), nausea (4). There were 2 pulmonary emboli. The PK of paclitaxel and carboplatin have been characterized to assess the effect of Avastin on systemic drug exposure. Conclusions: This regimen appears safe. PK results confirm no negative interaction with bev. Updated results will be available. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech
Biologic Properties of Cell Lines Derived From Canine Mammary Carcinomas23
Authors: Lauren G. Wolfe, Bonnie Buxton Smith, Maria A. Toivio-Kinnucan, Eva A. Sartin, Robert P. Kwapien, Ralph A. Henderson, Stephen Barnes
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Biologic Properties of Cell Lines Derived From Canine Mammary Carcinomas Get access Lauren G. Wolfe, Lauren G. Wolfe Search for other works by this author on: Oxford Academic PubMed Google Scholar Bonnie Buxton Smith, Bonnie Buxton Smith Search for other works by this author on: Oxford Academic PubMed Google Scholar Maria A. Toivio-Kinnucan, Maria A. Toivio-Kinnucan Search for other works by this author on: Oxford Academic PubMed Google Scholar Eva A. Sartin, Eva A. Sartin Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert P. Kwapien, Robert P. Kwapien Search for other works by this author on: Oxford Academic PubMed Google Scholar Ralph A. Henderson, Ralph A. Henderson Search for other works by this author on: Oxford Academic PubMed Google Scholar Stephen Barnes Stephen Barnes Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 77, Issue 3, September 1986, Pages 783–792, https://doi.org/10.1093/jnci/77.3.783 Published: 01 September 1986 Article history Received: 20 November 1985 Accepted: 12 May 1986 Published: 01 September 1986
Prognostic significance of serum vascular endothelial growth factor and angiopoietin-2 in lung cancer
Authors: Pinar Akin Kabalak, Aydin Çiledag, Gökhan Çelik, Nalan Demir, Cabir Yüksel, Gözde Köycü, Derya Gökmen Öztuna, Abbas Taner, Akin Kaya, Hakan Kutlay, Ismail Savas, Numan Numanoglu
Journal: European Respiratory Journal (2013)

Introduction: VEGF and Ang-2 is major mediators play roles in tumour angiogenesis.We aimed to evaluate relation between mediators and prognosis in lung cancer.   Method: Patients and healthy volunteers had been evaluated prospectively.VEGF and Ang-2 were measured by venous samples using ELISA.   Findings: Serum VEGF levels in patients with lung cancer (n=100) and control group (n=30) were 2308pg/ml and 2433pg/ml respectively. VEGF levels in SCLC (1013pg/ml) were significantly lower than NSCLC (2633pg/ml) and controls (p=0.005 and p=0.003).Survival analyses couldn’t be performed for VEGF due to elevation in control group.Patients had higher Ang-2 levels than controls (23395pg/ml vs 4025pg/ml and p  Mediators had highest correlation in stage IIA however according to TNM staging had a weak but positive correlation (p=0.1, r=0.638).   Results: VEGF was observed insufficient to distinct lung cancer.Although Ang-2 was usefull for differential diagnosis it had no effect on survival.Angiogenesis is a complicated process, tumour is heterogeneous so it should be more significant to study mediators on tumour tissue.
Growth Characteristics of Transplanted Normal Bladder Epithelium in Fischer Rats. I. Histology 2
Authors: S. Yalciner, G. H. Friedell
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Growth Characteristics of Transplanted Normal Bladder Epithelium in Fischer Rats. I. Histology Get access S. Yalciner, S. Yalciner Research Associate, Department of Pathology, University of Massachusetts Medical School, Worcester, Mass Search for other works by this author on: Oxford Academic PubMed Google Scholar G. H. Friedell G. H. Friedell Chief of Pathology, St. Vincent Hospital, and Professor of Pathology, University of Massachusetts Medical School, Worcester, Mass. 01610 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 5, November 1973, Pages 1719–1721, https://doi.org/10.1093/jnci/51.5.1719 Published: 01 November 1973 Article history Received: 03 August 1973 Accepted: 03 August 1973 Published: 01 November 1973
Safety and Efficacy of Concurrent Chemoradiotherapy for Advanced Esophagogastric Junction Squamous Cell Carcinoma
Authors: Kiyomi Sumita, Takahiro Tsushima, Satoshi Hamauchi, Akiko Todaka, Tomoya Yokota, Nozomu Machida, Kentaro Yamazaki, Akira Fukutomi, Yusuke Onozawa, Hirofumi Yasui
Journal: Annals of Oncology (2014)
Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial.
Authors: J Pont, W Höltl, D Kosak, E Machacek, H Kienzer, H Julcher, N Honetz
Journal: Journal of Clinical Oncology (1990)

Based on the results of a retrospective study, which found blood vessel invasion to be the most important prognostic factor in clinical stage I nonseminomatous testicular germ cell cancer (NSTGCC I), a prospective study was started in 1985 which assigned NSTGCC I patients without evidence of vascular invasion to surveillance and patients with vascular invasion to two cycles of adjuvant chemotherapy with cisplatin, etoposide, and bleomycin. Twenty-two patients entered the surveillance group and 18 patients received adjuvant chemotherapy. Median follow-up is 30 months (3 to 50 months). Relapses occurred in three patients (7.5%), one in the surveillance group (4.5%), two in the chemotherapy group (11%). Thirty-eight patients (95%) are alive and without evidence of disease. Two patients of the adjuvant-treated group died, one of progressive germ cell cancer and one of lung cancer. We conclude that low- and high-risk NSTGCC I patients can be identified by considering blood vessel invasion. The presence of embryonal carcinoma and vascular invasion seem to be interrelated prognostic factors, because in 94% of vessel invasion the invading element was embryonal carcinoma. The exclusion of patients with vascular invasion from surveillance decreases relapse rates remarkably. Adjuvant chemotherapy diminishes relapse rates in high-risk patients but does not entirely prevent relapse.
Article on Colombia should have been more objective
Authors: H. De la Calle-Lombana
Journal: BMJ (1999)

EDITOR—We Colombians must cope with cliches about drugs, violence, and underdevelopment. Although we have enormous problems, Veeken's article on Colombia lacks objectivity and fairness. It is based on prejudices arising from personal experiences, which he extends to the whole country. The BMJ should adopt a scientific approach to articles on health in Colombia instead of publishing subjective generalisations.

According to a 1997 United Nations report, Colombia's human development index (which measures personal income, life expectancy, health, and …